Status:
COMPLETED
Phase II Study of Pandemic Influenza Vaccine
Lead Sponsor:
Seqirus
Conditions:
Influenza
Eligibility:
All Genders
18-64 years
Phase:
PHASE2
Brief Summary
The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is the leading candidate to cause the next influenza pandemic. This study will ...
Eligibility Criteria
Inclusion
- Healthy Adults
Exclusion
- Previous vaccination with an influenza Vaccine containing the H5N1 strain
- History of clinically significant medical conditions
- History of Guillian-Barre Syndrome or active Neurological disease
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
End Date :
September 1 2006
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00320346
Start Date
July 1 2006
End Date
September 1 2006
Last Update
July 19 2016
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
CMAX, a division of IDT Australia
Adelaide, South Australia, Australia
2
Murdoch Childrens Research Institute
Melbourne, Victoria, Australia, 3052
3
Princess Margaret Hospital for Children
Perth, Western Australia, Australia